Clinical Trial Update: First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma [Phase 3]

View source ↗

Summary

Amgen's Phase 3 trial evaluating rilotumumab for MET-positive gastric/GEJ adenocarcinoma was terminated, indicating the study did not proceed to completion as p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma
• Lower Esophageal Adenocarcinoma

Drugs mentioned

• Rilotumumab (rilotumumab)

Snippet

Sponsor: Amgen | Conditions: Gastric Cancer | Phase 3 | Status: TERMINATED